Drug samples found sub-standard
After the establishment of certain medicines, manufactured by two Barotiwala-based pharmaceutical units, as sub-standard during the laboratory examination, the state drugs department on Saturday asked the managements of pharmaceutical companies concerned to withdraw its stock of particular batch from the market, failing which stringent action would be initiated in accordance with the law.Updated: Jun 01, 2013, 20:33 IST
After the establishment of certain medicines, manufactured by two Barotiwala-based pharmaceutical units, as sub-standard during the laboratory examination, the state drugs department on Saturday asked the managements of pharmaceutical companies concerned to withdraw its stock of particular batch from the market, failing which stringent action would be initiated in accordance with the law.
The authorities have further imposed a blanket ban on the sale and distribution of medicines, declared sub-standard by the Central Drug Standard Control Organisation (CDSCO) recently.
Earlier, the CDSCO authorities had placed a particular batch of Vibeltone tablets, DYKAY SP tablets, Alphadol capsules and Clavmax tablets on the list of sub-standard medicines in March.
The samples of Vibeltone tablet being manufactured by Paonta Sahib-based Laborate Pharmaceutical and DYKAY SP tablets manufactured by Persun Biotech Limited, Nurpura, in Kangra district were lifted by the Assam drug department in March.
Similarly, the samples of Alphadol capsules and Clavmax manufactured by Panacea Biotech Limited and Polo Pharmaceutical Company, Baddi, were lifted by CDSCO at Mumbai and Kolkatta and were sent for analysis to its Kolkata-based laboratory. Both the medicines were found sub-standard during the examination.
Prior to this, the samples of Telmisartan and Hydrochlorothiazide, manufactured by Micro Lab Limited, Baddi, and Spasdor and Paracetamol tablets manufactured by Japsi Chemical Pharmaceutical, Paonta Sahib, were also found below standard in CDSCO's Chandigarh laboratory in January.
Sources in the department revealed that the samples of batch number ULT 3257 of Rabby 20 manufactured in February 2012 by Ultratech Pharmaceuticals, Barotiwala, were lifted by CDSCO, Chennai, while samples of batch number S752887 of MEGARAB-20 tablets manufactured by Scott-Edil Pharmacia Jharmajri, Barotiwala, in July 2012 were lifted by the Assam drug department.
During the examinations, both the medicines were found below standard, following which CDSCO officials placed the medicines on the list of sub-standard, thereby brining the role of officials concerned of the Himachal drug department under scanner.
"The department after the receipt of information concerning failure of samples of medicines directed the two pharma units to immediately withdraw its stock from the markets," said drug controller Navneet Marwah.
He said the sale and distribution of the drugs in question have been banned across the state. Marwah said the department would launch a massive campaign against all such manufacturers to ensure production of quality medicines in future.